126430-46-4

Usage

Uses

Used in Perfume and Fragrance Industry:
BENZYL 4-BROMOBUTANOATE is used as a fragrance ingredient for its pleasant odor, contributing to the creation of various scents in perfumes and other fragranced products.
Used in Food and Beverage Industry:
In the food and beverage industry, BENZYL 4-BROMOBUTANOATE is used as a flavoring agent to enhance the taste and aroma of different food products and beverages.
Used in Organic Synthesis:
BENZYL 4-BROMOBUTANOATE is utilized as an intermediate in the synthesis of other organic compounds, playing a crucial role in the development of new chemical entities for various applications.

InChI:InChI=1/C11H13BrO2/c12-8-4-7-11(13)14-9-10-5-2-1-3-6-10/h1-3,5-6H,4,7-9H2

Upstream product

• 927-58-2 4-bromobutyroyl chloride 
• 100-51-6 benzyl alcohol 
• 2623-87-2 bromobutyric acid 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 168975-95-9 4-benzyl 1,1-di-tert-butyl butane-1,1,4-tricarboxylate 
• 158147-50-3 4-(1,2,4-triazol-1-yl)butyric acid benzyl ester 
• 608527-28-2 4-(N-benzyloxy-N-tert-butoxycarbonylamino)-butyric acid benzyl ester 
• 813432-36-9 4-[7-(3-benzyloxycarbonyl-propoxy)naphthalen-2-yloxy]butyryl-Val-Leu-Val-OMe 
• 813432-37-0 4-[7-(3-benzyloxycarbonyl-propoxy)quinolin-2-yloxy]butyryl-Val-Leu-Val-OMe 
• 608527-30-6 4-(N-benzyloxy-N-formylamino)-butyric acid benzyl ester 
• 608527-29-3 4-benzyloxyamino-butyric acid benzyl ester 
• 608527-31-7 4-(N-acetyl-N-benzyloxyamino)-butyric acid benzyl ester 
• 608527-32-8 4-(N-benzyloxy-N-isobutyrylamino)-butyric acid benzyl ester 
• 608527-33-9 4-(N-benzyloxy-N-2,2-dimethylpropionylamino)-butyric acid benzyl ester 
• 608527-35-1 4-(N-benzyloxy-N-2-furoylamino)-butyric acid benzyl ester 
• 608527-34-0 4-(N-benzoyl-N-benzyloxyamino)-butyric acid benzyl ester 
• 608527-38-4 4-(N-benzyloxy-N-1-naphthoylamino)-butyric acid benzyl ester 
• 608527-36-2 4-[N-benzyloxy-N-(4-phenyl-benzoyl)amino]-butyric acid benzyl ester 

Relevant academic research and scientific papers

PANTETHEINE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I), (II), or (II'): (I), (II), (II'), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

Spontaneously Blinking Fluorophores Based on Nucleophilic Addition/Dissociation of Intracellular Glutathione for Live-Cell Super-resolution Imaging

Single-molecule localization microscopy (SMLM) allows the reconstruction of super-resolution images but generally requires prior intense laser irradiation and in some cases additives to induce blinking of conventional fluorophores. We previously introduced a spontaneously blinking rhodamine fluorophore based on an intramolecular spirocyclization reaction for live-cell SMLM under physiological conditions. Here, we report a novel principle of spontaneous blinking in living cells, which utilizes reversible ground-state nucleophilic attack of intracellular glutathione (GSH) upon a xanthene fluorophore. Structural optimization afforded two pyronine fluorophores with different colors, both of which exhibit equilibrium (between the fluorescent dissociated form and the nonfluorescent GSH adduct form) and blinking kinetics that enable SMLM of microtubules or mitochondria in living cells. Furthermore, by using spontaneously blinking fluorophores working in the near-infrared (NIR) and green ranges, we succeeded in dual-color live-cell SMLM without the need for optimization of the imaging medium.

Cationic Lipid

The present invention provides a cationic lipid which is able to be used for nucleic acid delivery to the cytoplasm. A cationic lipid according to the present invention is, for example, a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, wherein L1 and L2 independently represent an alkylene group having 3 to 10 carbon atoms; R1 and R2 independently represent an alkyl group having 4 to 24 carbon atoms or an alkenyl group having 4 to 24 carbon atoms; R3 represents an alkyl group having 1 to 3 carbon atoms; and X1 represents a single bond or CO—O—.

CATIONIC LIPID

The present invention provides a cationic lipid which is able to be used for nucleic acid delivery to the cytoplasm. A cationic lipid according to the present invention is, for example, a compound represented by formula (1a) or a pharmaceutically acceptable salt thereof. (In formula (1a), each of L1 and L2 independently represent an alkylene group having 3-10 carbon atoms; each of R1 and R2 independently represent an alkyl group having 4-22 carbon atoms or an alkenyl group having 4-22 carbon atoms; X1 represents a single bond or -CO-O-; and ring P represents one of formulae (P-1) to (P-5).)(In formulae (P-1) to (P-5), R3 represents an alkyl group having 1-3 carbon atoms.)

Cation-π interactions contribute to substrate recognition in γ-butyrobetaine hydroxylase catalysis

γ-Butyrobetaine hydroxylase (BBOX) is a non-heme FeII- and 2-oxoglutarate-dependent oxygenase that catalyzes the stereoselective hydroxylation of an unactivated C-H bond of γ-butyrobetaine (γBB) in the final step of carnitine biosynthesis. BBOX contains an aromatic cage for the recognition of the positively charged trimethylammonium group of the γBB substrate. Enzyme binding and kinetic analyses on substrate analogues with P and As substituting for N in the trimethylammonium group show that the analogues are good BBOX substrates, which follow the efficiency trend N+>P+>As+. The results reveal that an uncharged carbon analogue of γBB is not a BBOX substrate, thus highlighting the importance of the energetically favorable cation-π interactions in productive substrate recognition. What's in the BBOX? Enzyme kinetics and substrate binding studies reveal that γ-butyrobetaine hydroxylase (BBOX)-catalyzed stereoselective hydroxylation of γ-butyrobetaine involves energetically favorable cation-π interactions.

CRYSTALLINE FORMS OF A THERAPEUTIC COMPOUND AND USES THEREOF

Disclosed herein are certain crystalline forms of Compound 5, N-(5-((2-(4-(2-oxa-7- azaspiro[3.5]nonan-7-yl)butanamido)imidazo[1,2-0]pyridazin-6-yl)oxy)-2-methylphenyl)-1,3- dimethyl-1 /-/-pyrazole-5-carboxamide, as well as pharmaceutical compositions comprising the crystalline forms. The present disclosure further relates to methods for treating or preventing diseases or disorders using the crystalline forms or pharmaceutical compositions thereof in a subject in need thereof, including diseases or disorders associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor signaling pathway (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases and ocular diseases.

Synthesis and evaluation of phenoxymethylbenzamide analogues as anti-trypanosomal agents

The synthesis and anti-trypanosomal activity of a compound library based on a phenoxymethylbenzamide hit discovered in a high throughput screen is described. Several of the analogues exhibited potent activity against Trypanosoma brucei rhodesiense, a human infective strain of the trypanosome parasite, that serve as lead compounds for further optimisation. This journal is

MRI CONTRAST AGENTS

The present invention relates to MRI based imaging. In particular, the present invention provides MRI contrast agents targeted to a HaloTag protein with tunable relaxation properties thereby providing optimal relaxivity for low field strength imaging and the other optimal relaxivity for high field strength imaging. Moreover, the MRI contrast agents are used to detect gene expression (of a gene of interest) in real time in vivo, to detect changes in gene expression (of a gene of interest) over time in, for example, an individual organism, to detect gene expression changes (of a gene of interest) in response to therapeutics, in cell labeling for MR imaging, in clinical diagnostics, and in theranostics.

Reporter protein-targeted probes for magnetic resonance imaging

Contrast agents for magnetic resonance imaging are frequently employed as experimental and clinical probes. Drawbacks include low signal sensitivity, fast clearance, and nonspecificity that limit efficacy in experimental imaging. In order to create a bioresponsive MR contrast agent, a series of four Gd(III) complexes targeted to the HaloTag reporter were designed and synthesized. HaloTag is unique among reporter proteins for its specificity, versatility, and the covalent interaction between substrate and protein. In similar systems, these properties produce prolonged in vivo lifetimes and extended imaging opportunities for contrast agents, longer rotational correlation times, and increases in relaxivity (r1) upon binding to the HaloTag protein. In this work we report a new MR contrast probe, 2CHTGd, which forms a covalent bond with its target protein and results in a dramatic increase in sensitivity. A 6-fold increase in r1, from 3.8 to 22 mM-1s-1, is observed upon 2CHTGd binding to the target protein. This probe was designed for use with the HaloTag protein system which allows for a variety of substrates (specific for MRI, florescence, or protein purification applications) to be used with the same reporter.

Tuning the polarity of hierarchically assembled helicates

Catechol ligands bearing ester groups in 3-position (1a,b, 2) are building blocks for the formation of triply lithium-bridged dinuclear helicate-type complexes [Li1a,b,2)i-. Attachment of appropriate functionalities at the ester unit allows the fine tuning of the polarity of the compounds to afford solubility in highly nonpolar as well as highly polar solvents. The investigations show that the internal dinuclear core is stable in a broad variety of solvents, even in water. Georg Thieme Verlag Stuttgart ? New York.